Insulin secretagogues including sulfonylureas, glinides and incretin-related drugs such as dipeptidyl peptidase 4 (DPP-4) inhibitors and glucagon-like peptide-1 receptor agonists are widely used for treatment of type 2 diabetes. In addition, glucokinase activators and G-protein-coupled receptor 40 (GPR40) agonists also have been developed, although the drugs are not clinically usable. These different drugs exert their effects on insulin secretion by different mechanisms. Recent advances in β-cell signalling studies have not only deepened our understanding of insulin secretion but also revealed novel mechanisms of insulin secretagogues. Clarification of the signalling mechanisms of the insulin secretagogues will contribute to improved drug therapy for diabetes.
| INTRODUCTION
Insulin secretion from pancreatic β-cells plays the central role in maintenance of glucose homeostasis. The most prominent feature of pancreatic β-cells is secretion of insulin in response to changes of the extracellular (blood) glucose. The β-cell possesses the capacity to sense circulating glucose levels. Glucose is transported into the β-cell through facilitated glucose transporters (GLUTs) and then is phosphorylated by glucokinase (GK) in the glycolytic pathway. GK (hexokinase IV: a high Km isoform of hexokinase) catalyses the formation of glucose 6-phosphate from glucose without allosteric inhibition of the product, and is therefore considered to be the glucose sensor of insulin secretion in pancreatic β-cells. Glucose-induced insulin secretion (GIIS) comprises 2 pathways: the triggering pathway and the metabolic amplifying pathway. 1 The former involves closure of the ATP-sensitive K + channel (K ATP channels) by increased ATP concentration due to glucose metabolism, which is followed by Ca is the most common management tool for T2D. Among the various AHAs, insulin secretagogues are widely used in the treatment of T2D. Clarification of the mechanisms of β-cell signalling will deepen
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our understanding of the mechanisms of both insulin secretion and the action of insulin secretagogues and enable improved therapy for T2D. Here, we review the insulin secretagogues and their signalling mechanisms. We also introduce our strategy of development of novel small molecules that stimulate insulin secretion.
| SIGNALLING MECHANISMS OF SULFONYLUREAS AND GLINIDES
The K ATP channel in the β-cells is a primary target of sulfonylureas and glinides. The β-cell K ATP channel comprises the inwardly rectify- Figure 1 ). On the other hand, SUR2 contains only the B-site. 6 The A-site is located in the transmembrane domain 2 of SUR1, and is involved in binding of the sulfonylurea structure and the glinides such as nateglinide and mitiglinide. Ser1237 in the eighth cytoplasmic loop is important for the specificity of sulfonylurea-SUR1 binding. 10 The B-site is located in the third cytoplasmic loop and is involved in binding of repaglinide and meglitinide as well as benzamide and its related structure 11 ( Table 1 ). The N-terminus of Kir6.2 is also involved in binding of benzamide and its related structure. 12 Recent advance in cryo-electron microscopy technology has revealed the molecular structure of the β-cell K ATP channel and sulfonylurea binding to the channel. 13, 14 Binding of sulfonylureas to SUR1 closes the K ATP channels, depolariz- 
| SIGNALLING MECHANISMS OF INCRETINS AND INCRETIN-RELATED DRUGS
The incretins GIP and GLP-1 potentiate insulin secretion at elevated blood glucose levels, thus preventing postprandial hyperglycemia. Utilizing the glucose-dependent effect of incretins, incretin-related drugs have been developed and are currently used worldwide. 21 Incretinrelated drugs are classified into 2 groups: incretin enhancers and incretin mimetics. 22 The former includes DPP-4 inhibitors, which increase the levels of active forms of both GLP-1 and GIP. The latter includes GLP-1 receptor agonists, which directly activate GLP-1-mediated signalling in β-cells. Although β-cell sensitivity to GIP is reduced in patients with T2D, near-normalization of blood glucose has been found to improve β-cell responsiveness to both GLP-1 and GIP. 23 cAMP is a crucial signal in IIIS. cAMP signalling potentiates insulin secretion not only by PKA-dependent but also by Epac2A-dependent mechanisms. Epac2 (cAMP-GEFII) was identified as a cAMP-binding protein that interacts with the sulfonylurea receptor SUR1, the regulatory subunit of the pancreatic β-cell K ATP channel. mobilization. 34 GLP-1 also has been suggested to increase the activity of GK, the rate-limiting enzyme in glycolysis, through Epac2A-Rim2α-Rab3 signalling. 42 Thus, the insulintropic signalling mechanisms downstream of Epac2A are complex. 43 In addition, dimethyl-glutamate, a membrane-permeable glutamate precursor that is converted to glutamate in cells, amplifies both the first and second phases of glucose-induced insulin granule exocytosis, mimicking the effect of incretins. Glutamate in the cytosol is known to be transported into secretory vesicles through vesicular glutamate transporters (VGLUTs). 46 Pharmacological inhibition of VGLUTs in MIN6-K8 β-cells, knockdown of VGLUT1 in MIN6-K8 β-cells or VGLUT1 global knockout in mice did not affect GIIS, but it did reduce IIIS, suggesting that glutamate transport into insulin granules through VGLUT1 is required for IIIS. 43 Thus, cytosolic glutamate acts as a critical amplifying signal in IIIS (Figure 2 ). On the other hand, mitochondrial glutamate was previously proposed to be a signal for GIIS, 47 but this notion has been controversial, 48, 49 and the mechanism by which mitochondrial glutamate stimulates insulin secretion is still unknown. Glutamate production in pancreatic islets of diabetic and obese animal models also was examined. Goto-Kakizaki rats, a model of diabetes with impaired insulin secretion, somewhat retain IIIS. In contrast, Zucker fatty rats, a model of obesity, show no IIIS. Glutamate production by glucose stimulation was found to be increased significantly in the islets of Goto-Kakizaki rats but not in those of Zucker fatty rats. 43 Thus, IIIS is correlated with glutamate produced by glucose stimulation in β-cells.
Impaired β-cell glutamate signalling (eg, impaired glutamate production and/or impaired glutamate transport into insulin granules) may well In clinical settings, combination therapies of incretin-related drugs and sulfonylureas are often used for glycemic control in T2D 51, 52 ; however, combination of DPP-4 inhibitors and sulfonylureas can lead to severe hypoglycemia in some cases. 53 As described above, as
Epac2A is a target of both incretin/cAMP signalling and sulfonylureas ( Figure 3A) , it is probably that incretin and sulfonylurea has a combinatorial effect on insulin secretion through Epac2A. Indeed, strong augmentation of insulin secretion by combination of GLP-1 and glibenclamide or glimepiride was found in wild-type mice, but the combinatorial effect was markedly reduced in Epac2A global knockout mice 54 ( Figure 3B ). This augmenting effect through Epac2A/Rap1 signalling is a possible mechanism by which sulfonylurea uncouples the glucose-dependency of the effect of GLP-1. 55 In contrast, the combi- . 53 Among the following 3 combination therapies, sitagliptin plus glibenclamide, sitagliptin plus glimepiride and sitagliptin plus gliclazide, sitagliptin plus gliclazide was estimated to cause hypoglycemia at the lowest incidence rate, based on adjustment of the number of prescriptions for each sulfonylurea. 53 Distinct effects on Epac2A activation among different sulfonylureas may therefore account, in part, for the different hypoglycemic effects in T2D patients treated with combination therapy of a DPP-4 inhibitor and different sulfonylureas.
"
Interaction between incretin/cAMP and sulfonylurea through Epac2A/Rap1 signalling provides the basis for the effects of combination therapies of incretin-related drugs and sulfonylureas. 
| GPR40 agonists
Free fatty acids have long been known to potentiate insulin secretion in a glucose-dependent manner. [56] [57] [58] GPR40, a member of the GPCR family, was identified as a receptor for fatty acids in 2003. 59, 60 GPR40 is expressed at high levels in pancreatic β-cells, and mediates amplification of insulin secretion by long chain fatty acids in a glucosedependent manner. 60 GPR40 is coupled to the heterotrimeric G protein Gα q/11. 59-61 Activation of Gα q/11 promotes PLC-mediated hydrolysis of PIP 2 into DAG and IP 3 , which respectively activates protein kinase C (PKC) and mobilizes Ca 2+ from the ER store ( Figure 3A) . The role of GPR40 in potentiation of insulin secretion has been confirmed by various studies including pharmacological inhibition, 62 knockdown in β-cell lines and generation of knockout mouse. 61 In addition, overexpression of GPR40 in pancreatic β-cells has been shown to improve insulin secretion and glucose tolerance in genetically diabetic mice. 63 It has been shown that Ca 2+ influx rather than Ca 2+ mobilization from the ER is important for GPR40-mediated insulin secretion. 64 A recent study also showed that generation of DAG and subsequent activation of the Although the target of DSC108 is the β-cell K ATP channel, which is already known, in silico similarity search is a powerful and effective approach for the discovery of novel therapeutic compounds ( Figure 4 ).
"
In silico similarity search combined with insulin secretion assay is a useful method to identify novel compounds that can lead to the development of new antidiabetic drugs. 
